Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT00112567
First received: June 2, 2005
Last updated: September 17, 2010
Last verified: September 2010

June 2, 2005
September 17, 2010
April 2003
Not Provided
Safety [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00112567 on ClinicalTrials.gov Archive Site
  • Risk of severe graft-versus-host disease [ Designated as safety issue: No ]
  • Kinetics of immune reconstitution [ Designated as safety issue: No ]
  • Risk of life-threatening infections [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants

RATIONALE: Chemotherapy, such as fludarabine and thiotepa, and radiation therapy may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow. Giving healthy stem cells from a donor whose blood closely resembles the patient's blood will help the patient's bone marrow make new stem cells that become red blood cells, white blood cells, and platelets.

PURPOSE: This phase I/II trial is studying the side effects of total-body irradiation, fludarabine, and thiotepa and to see how well they work in treating young patients who are undergoing a donor stem cell transplant for hematologic cancer.

OBJECTIVES:

Primary

  • Determine the safety of a conditioning regimen without anti-thymocyte globulin comprising total body irradiation, thiotepa, and fludarabine followed by CD34-positive-selected haploidentical allogeneic peripheral blood stem cell transplantation in young patients with life-threatening hematologic malignancies.

Secondary

  • Determine the risk for severe graft-vs-host disease in patients treated with this regimen.
  • Determine the kinetics of immune reconstitution in patients treated with this regimen.
  • Determine the risk for life-threatening infections in patients treated with this regimen.

OUTLINE:

  • Conditioning regimen: Patients 7 years of age and under undergo total body irradiation twice daily on days -9 to -7. Patients over 7 years of age undergo total body irradiation once on day -7. All patients receive fludarabine IV once daily on days -6 to -2 and thiotepa IV over 2 hours twice on day -5.
  • CD34-positive (CD34+)-selected haploidentical allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo CD34+-selected allogeneic PBSCT on days 0 and 2.

Patients with acute lymphoblastic leukemia or CNS disease also receive methotrexate intrathecally twice before transplantation and 4 times after day 35 post-transplantation. Male patients with lymphoid malignancies undergo additional radiotherapy to the testes.

After completion of study treatment, patients are followed for at least 100 days, at 1 year, and then periodically thereafter.

PROJECTED ACCRUAL: A total of 20 patients (10 patients ≤ 7 years of age and 10 patients > 7 years of age) will be accrued for this study within 3 years.

Interventional
Phase 1
Phase 2
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic Syndromes
  • Drug: fludarabine phosphate
  • Drug: thiotepa
  • Procedure: peripheral blood stem cell transplantation
  • Radiation: radiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
July 2007
Not Provided

DISEASE CHARACTERISTICS:

  • Diagnosis of a life-threatening hematologic malignancy, including any of the following:

    • Acute leukemia advanced beyond first remission
    • Acute leukemia in first remission* with very high-risk prognostic features, including any of the following:

      • Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
      • ALL or acute myeloid leukemia (AML) with 11q23 chromosomal abnormality
      • Hypodiploid ALL
      • Failed to achieve first remission within 1 month after induction therapy
      • Secondary AML
    • Myelodysplastic syndromes with International Prognostic Index score > 1
    • Chronic myelogenous leukemia in accelerated or blast phase NOTE: *Must be approved by PCC
  • Haploidentical family donor available

    • No suitable HLA-matched related or unrelated donor available
    • No related donor mismatched for a single HLA-A, -B, -C, -DRB1, or -DQB1 antigen available

PATIENT CHARACTERISTICS:

Age

  • Under 21

Performance status

  • Not specified

Life expectancy

  • At least 6 months

Hematopoietic

  • Not specified

Hepatic

  • SGPT and SGOT < 2 times upper limit of normal (ULN)*
  • Bilirubin < 2 times ULN* NOTE: *Unless due to malignancy

Renal

  • Not specified

Cardiovascular

  • Ejection fraction ≥ 45%

Pulmonary

  • DLCO ≥ 60% of predicted

Other

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No second bone marrow transplantation, after a first regimen containing total body irradiation
  • No concurrent growth factors until day 21 post-transplantation

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • See Biologic therapy

Surgery

  • Not specified
Both
up to 20 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00112567
1629.00, FHCRC-1629.00, CDR0000430650
Not Provided
Not Provided
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Principal Investigator: Ann E. Woolfrey, MD Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP